You may not automatically think of pharma giant Johnson & Johnson (NYSE: JNJ) as a high-growth company. Yes, J&J is practically a household name, thanks to consumer products like Aveeno lotions and Band-Aid bandages. But these and other products haven't driven much growth over the past several years. And that may have pushed away some investors.

Things are changing at J&J though -- and a new era of growth might have already started. The star of the show? J&J's medtech business. It posted a double-digit increase in revenue in the second quarter. And more may be on the way.

Does this mean it's time to buy this big pharma stock? Let's find out.

Continue reading

Source Fool.com